Abcam, ab263405, Human UBE2A knockout HEK-293T cell lysate

Size: 1Kit
UBE2A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 8 bp deletion in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 8 bp deletion in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UBE2A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Rad6 also known as ubiquitin-conjugating enzyme E2 A (UBE2A) is an enzyme with a molecular weight of approximately 17 kDa. This enzyme plays an essential role in the ubiquitination process where it catalyzes the transfer of ubiquitin to substrate proteins. Rad6 is expressed in various tissues with significant activity observed in the testis and brain suggesting its involvement in cell division and development.
Biological function summary
Rad6 functions as part of a larger protein complex involved in the DNA damage repair process. It collaborates with the RAD6 epistasis group which ensures the maintenance of genomic stability. Rad6 as a ubiquitin-conjugating enzyme interacts with E3 ubiquitin ligases facilitating the ubiquitination of target proteins that require degradation or regulation in response to DNA damage. This activity is vital for DNA repair mechanisms like post-replication repair (PRR) which protects cells from mutagenic events.
Pathways
Rad6 integrates into critical biological processes including the ubiquitin-proteasome pathway and the DNA repair pathway. Within the ubiquitin-proteasome system Rad6 aids in tagging proteins for degradation thereby regulating protein levels and cellular functions. It connects to other proteins like E3 enzymes and RAD18 in the DNA repair pathway. Its activity in DNA repair ensures the appropriate response to DNA damage coordinating with other mechanistic proteins to maintain genomic stability.
Rad6 shows significant association with cancer and neurodegenerative conditions. Changes in Rad6 activity can lead to abnormal cell cycle progression contributing to oncogenesis particularly in breast and ovarian cancers. Rad6 interacts with proteins such as BRCA1 a tumor suppressor implicating its role in hereditary breast cancer. Additionally its dysfunction in the brain may relate to Alzheimer's disease highlighting its connection to neuroprotective pathways and protein degradation systems.